The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of our common shares by the selling shareholder, Armistice Capital Master Fund.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Is MDCX a Buy, Before Earnings?
- Optimistic Buy Rating for Medicus Pharma Ltd Driven by Promising SkinJect Developments and Strategic Initiatives
- Medicus Pharma Seeks FDA Priority Voucher for Innovative Skin Cancer Treatment
- Medicus Pharma announces filing of CNPV application for SKNJCT-003
- Medicus Pharma Reports Q3 Loss Amid Strategic Growth